INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $330,563 | -20.1% | 6,346 | -2.8% | 0.04% | -18.2% |
| Q2 2023 | $413,543 | +13.6% | 6,531 | -2.8% | 0.04% | +7.3% |
| Q1 2023 | $363,942 | +5.2% | 6,721 | +2.8% | 0.04% | -2.4% |
| Q4 2022 | $345,885 | -75.4% | 6,536 | -78.4% | 0.04% | -76.8% |
| Q3 2022 | $1,407,000 | -19.7% | 30,236 | -1.5% | 0.18% | -12.6% |
| Q2 2022 | $1,753,000 | +1.3% | 30,703 | -2.0% | 0.21% | +1.5% |
| Q1 2022 | $1,731,000 | +2.7% | 31,341 | -2.7% | 0.20% | +28.3% |
| Q4 2021 | $1,686,000 | +3.3% | 32,205 | -26.4% | 0.16% | -8.6% |
| Q3 2021 | $1,632,000 | -50.8% | 43,780 | -51.9% | 0.17% | -24.0% |
| Q2 2021 | $3,316,000 | +123.5% | 90,938 | +107.9% | 0.23% | +30.9% |
| Q1 2021 | $1,484,000 | +6.2% | 43,741 | -0.4% | 0.18% | -11.6% |
| Q4 2020 | $1,397,000 | – | 43,929 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |